Renal Disease in Recipients of Nonrenal Solid Organ Transplantation

Seminars in Nephrology

Volumn 27, Issue 4, 2007, Pages 498-507

  Ojo, Akinlolu O ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Calcineurin inhibitors; cardiac transplantation; immunosuppressive drugs; liver transplantation; lung transplantation; nephrotoxicity

Indexed keywords

AMPHOTERICIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; LYMPHOCYTE ANTIBODY; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; DIALYSIS; DIET; GLOMERULOSCLEROSIS; HEMODIALYSIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; ORGAN TRANSPLANTATION; PREVALENCE; RISK FACTORS; WORLD HEALTH;

EID: 34347240943     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.03.010     Document Type: Article

References (95)

1. Meiser B., Reichart B., Adamidis I., et al. First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation. Am J Transplant 5 (2005) 827-831
2. Schlitt H.J., Barkmann A., Boker K.H.W., et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 357 (2001) 587-591
3. Nair S., Eason J., and Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transplantation 9 (2003) 126-129
4. Groetzner J., Kaczmarek I., Meiser B., et al. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure. J Heart Lung Transplant 23 (2004) 770-773
5. McGiffin D.C., Kirklin J.K., and Naftel D.C. Acute renal failure after heart transplantation and cyclosporine therapy. J Heart Transplant 4 (1985) 396-399
6. Greenberg A., Egel J.W., Thompson M.E., et al. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis 9 (1987) 12-22
7. Griffiths M.H., Crowe A.V., Papadaki L., et al. Cyclosporin nephrotoxicity in heart and lung transplant patients. QJM 89 (1996) 751-763
8. Gonwa T.A., Mai M.L., Melton L.B., et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy. Risk of development and treatment. Transplantation 72 (2001) 1934-1939
9. Greenberg A., Thompson M.E., Griffith B.J., et al. Cyclosporine nephrotoxicity in cardiac allograft patients-a seven-year follow-up. Transplantation 50 (1990) 589-593
10. Goldstein J., Thoua Y., Wellens F., et al. Cyclosporine nephropathy after heart and heart-lung transplantation. Proc Eur Dial Transplant Assoc 21 (1985) 973-981
11. van Gelder T., Balk A.H., Zietse R., et al. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant 13 (1998) 2322-2326
12. Satchithananda D.K., Parameshwar J., Sharples L., et al. The incidence of end-stage renal failure in 17 years of heart transplantation: a single center experience. J Heart Lung Transplant 21 (2002) 651-657
13. Stevens L.M., El-Hamamsy I., Leblanc M., et al. Continuous renal replacement therapy after heart transplantation. Can J Cardiol 20 (2004) 619-623
14. Canver C.C., Heisey D.M., and Nichols R.D. Acute renal failure requiring hemodialysis immediately after heart transplantation portends a poor outcome. J Card Surg 41 (2000) 203-206
15. Cruz D.N., and Perazella M.A. Acute renal failure after cardiac transplantation: a case report and review of the literature. Yale J Biol Med 69 (1996) 461-468
16. Rocha P.N., Rocha A.T., Palmer S.M., et al. Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality. Am J Transplant 5 (2005) 1469-1476
17. McCauley J., Van Thiel D.H., Starzl T.E., et al. Acute and chronic renal failure in liver transplantation. Nephron 55 (1990) 121-128
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39 Suppl 1 (2002) S1-S266
19. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003) 931-940
20. Zaltzman J.S., Pei Y., Maurer J., et al. Cyclosporine nephrotoxicity in lung transplant recipients. Transplantation 54 (1992) 875-878
21. Abreo K., Zibari G., and McDonald J. End-stage renal disease in liver transplants. Clin Transplant 12 (2001) 66-69
22. Goldstein D.J., Zuech N., Sehgal V., et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 63 (1997) 664-668
23. Kunst H., Thompson D., and Hodson M. Hypertension as a marker for later development of end-stage renal failure after lung and heart-lung transplantation: a cohort study. J Heart Lung Transplant 23 (2004) 1182-1188
24. Fisher N.C. Renal failure after lung transplantation. Lancet 352 (1998) 69-70
25. Fisher N.C., Nightingale P.G., Gunson B.K., et al. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 66 (1998) 59-66
26. Veillon S., Caillard S., Epailly E., et al. Chronic renal failure after cardiac transplantation: predictive factors and influence on mortality-results of a monocenter study in 141 patients. Transplant Proc 34 (2002) 2819-2820
27. Phan V., West L.J., Stephens D., et al. Renal complications following heart transplantation in children: a single-center study. Am J Transplant 3 (2003) 214-218
28. Pawarode A., Fine D.M., and Thuluvath P.J. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 9 (2003) 741-747
29. Lindelow B., Bergh C.H., Herlitz H., et al. Predictors and evolution of renal function during 9 years following heart transplantation. J Am Soc Nephrol 11 (2000) 951-957
30. Sehgal V., Radhakrishnan J., Appel G.B., et al. Progressive renal insufficiency following cardiac transplantation: cyclosporine, lipids, and hypertension. Am J Kidney Dis 26 (1995) 193-201
31. Wilkinson A.H., and Cohen D.J. Renal failure in the recipients of nonrenal solid organ transplants. J Am Soc Nephrol 10 (1999) 1136-1144
32. Myers B.D., Ross J., Newton L., et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 311 (1984) 699-705
33. Al Aly Z., Abbas S., Moore E., et al. The natural history of renal function following orthotopic heart transplant. Clin Transplant 19 (2005) 683-689
34. Klintmalm G.B., and Gonwa T.A. Nephrotoxicity associated with cyclosporine and FK506. Liver Transpl Surg 1 (1995) 11-19
35. Axelsen R.A., Crawford D.H., Endre Z.H., et al. Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology 27 (1995) 237-246
36. Coopersmith C.M., Brennan D.C., Miller B., et al. Renal transplantation following previous heart, liver, and lung transplantation: an 8-year single-center experience. Surgery 130 (2001) 457-462
37. Esposito C., Semeraro L., Bellotti N., et al. Risk factors for chronic renal dysfunction in cardiac allograft recipients. Nephron 84 (2000) 21-28
38. Hornberger J., Best J., Geppert J., et al. Risks and costs of end-stage renal disease after heart transplantation. Transplantation 66 (1998) 1763-1770
39. Lewis R.M., Verani R.R., Vo C., et al. Evaluation of chronic renal disease in heart transplant recipients: importance of pretransplantation native kidney histologic evaluation. J Heart Lung Transplant 13 (1994) 376-380
40. Hmiel S.P., Beck A.M., de la Morena M.T., et al. Progressive chronic kidney disease after pediatric lung transplantation. Am J Transplant 5 (2005) 1739-1747
41. Bennett W.M., DeMattos A., Meyer M.M., et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 50 (1996) 1089-1100
42. Young B.A., Burdmann E.A., Johnson R.J., et al. Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int 48 (1995) 431-438
43. Myers B.D., Sibley R., Newton L., et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33 (1988) 590-600
44. Myers B.D. Cyclosporine nephrotoxicity. Kidney Int 30 (1986) 964-974
45. Rubel J.R., Milford E.L., McKay D.B., et al. Renal insufficiency and end-stage renal disease in the heart transplant population. J Heart Lung Transplant 23 (2004) 289-300
46. Pichler R.H., Franceschini N., Young B.A., et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 6 (1995) 1186-1196
47. Kopp J.B., and Klotman P.E. Cellular and molecular mechanisms of cyclosporine nephrotoxicity. J Am Soc Nephrol 1 (1990) 162-179
48. Mason J., Muller-Schweinitzer E., Dupont M., et al. Cyclosporine and the renin-angiotensin system. Kidney Int 32 (1991) S28-S32
49. Gardiner D.S., Watson M.A., Junor B.J.R., et al. The effect of conversion from cyclosporine to azathioprine on renin-containing cells in renal allograft biopsies. Nephrol Dial Transplant 6 (1991) 363-367
50. Young E.W., Ellis C.N., Messana J.M., et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 46 (1994) 1216-1222
51. Bertani T., Ferrazzi P., Schieppati A., et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 40 (1991) 243-250
52. Langham R.G., Egan M.K., Dowling J.P., et al. Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 72 (2001) 1826-1829
53. Baan C.C., Balk A.H., Holweg C.T., et al. Renal failure after clinical heart transplantation is associated with the TGF-beta 1 codon 10 gene polymorphism. J Heart Lung Transplant 19 (2000) 866-872
54. Khanna A., Plummer M., Bromberek C., et al. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 62 (2002) 2257-2263
55. Campistol J.M., Inigo P., Jimenez W., et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 56 (1999) 714-719
56. Coupes B.M., Newstead C.G., Short C.D., et al. Transforming growth factor β1 in renal allograft recipients. Transplantation 57 (1994) 1727-1731
57. Sharma K., Eltayeb B.O., McGowan T.A., et al. Captopril-induced reduction of serum levels of transforming growth factor-β1 correlated with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 34 (1999) 818-823
58. Gavras H., Brunner H.R., and Laragh J.H. Renin and aldosterone and the pathogenesis of hypertensive vascular damage. Prog Cardiovasc Dis 17 (1974) 39-49
59. Rocha R., and Stier Jr. C.T. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12 (2001) 308-314
60. Silvestre J.-S., Heymes C., Oubénaïssa A., et al. Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99 (1999) 2694-2701
61. Brewster U.C., Setaro J.F., and Perazella M.A. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326 (2003) 15-24
62. Sato A., Funder J.W., and Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 12 (1999) 867-873
63. Ibrahim H.N., Rosenberg M.E., Greene E.L., et al. Aldosterone is a major factor in the progression of renal disease. Kidney Int Suppl 63 (1997) S115-S119
64. Hostetter T.H., Rosenberg M.E., Ibrahim H.N., et al. Aldosterone in progressive renal disease. Semin Nephrol 21 (2001) 573-579
65. Epstein M. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 40 (2001) 573-583
66. Ruiz-Ortega M., and Egido J. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 52 (1997) 1497-1510
67. Greene E.L., Kren S., and Hostetter T.H. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98 (1996) 1063-1068
68. Brown N.J., Vaughan D.E., and Fogo A.B. Aldosterone and PAI-1: implications for renal injury. J Nephrol 15 (2002) 230-235
69. Myers B.D., Sibley R., Newton L., et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33 (1988) 590-600
70. Seikaly M.G., Arant B.S.J., and Seney F.D.J. Endogenous angiotensin concentrations in specific intrarenal fulid compartments of the rat. J Clin Invest 86 (1990) 1352-1358
71. Wood A.J.J. Angiotensin receptors and their antagonists. N Engl J Med 334 (1996) 1649-1654
72. Wood A.J.J. Angiotensin receptors and their antagonists. N Engl J Med 86 (1990) 1352-1358
73. Langham R.G., Egan M.K., Dowling J.P., Gilbert R.E., and Thomson N.M. Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 72 (2001) 1826-1829
74. Feria I., Pichardo I., Juarez P., et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63 (2003) 43-52
75. Ahokas R.A., Warrington K.J., Gerling I.C., et al. Aldosteronism and peripheral blood mononuclear cell activation. A neuroendocrine-immune interface. Circ Res 93 (2003) e124-e135
76. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 5 (2005) 2273-2280
77. Kamar N., Allard J., Ribes D., et al. Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus. Clin Nephrol 63 (2005) 80-86
78. Shihab F.S., Bennett W.M., Yi H., et al. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 65 (2004) 1262-1271
79. Morales J.M., Wramner L., Kreis H., et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2 (2002) 436-442
80. Hocker B., Knuppel T., Waldherr R., et al. Recurrence of proteinuria 10 years post-transplant in NPHS2-associated focal segmental glomerulosclerosis after conversion from cyclosporin A to sirolimus. Pediatr Nephrol 21 (2006) 1476-1479
81. Boratynska M., Banasik M., Watorek E., et al. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 38 (2006) 101-104
82. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
83. Oteo J.F., Alonso-Pulpon L., Diez J.L., et al. Microangiopathic hemolytic anemia secondary to cyclosporine therapy in a heart and liver transplant recipient. J Heart Lung Transplant 15 (1996) 322-324
84. Guillemain R., Farge D., Amrein C., et al. Thrombotic microangiopathy with reversible acute renal failure in a cardiac transplant recipient under cyclosporin. Clin Nephrol 34 (1990) 237-238
85. Pillebout E., Nochy D., Hill G., et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 5 (2005) 1120-1129
86. Angermann C.E., Stork S., Costard-Jackle A., et al. Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients-the IMPROVED multi-centre study. Eur Heart J 25 (2004) 1626-1634
87. Shitrit D., Rahamimov R., Gidon S., et al. Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study. Kidney Int 67 (2005) 1471-1475
88. Baryalei M., Zenker D., Pieske B., et al. Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. Transplant Proc 35 (2003) 1539-1542
89. Groetzner J., Kur F., Spelsberg F., et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 23 (2004) 632-638
90. Kuo P.C., Luikart H., Busse-Henry S., et al. Clinical outcome of interval cadaveric renal transplantation in cardiac allograft recipients. Clin Transpl 9 (1995) 92-97
91. Molmenti E.P., Jain A.B., Shapiro R., et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis c viral infection. Transplantation 71 (2001) 267-271
92. Paramesh A.S., Roayaie S., Doan Y., et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transpl 18 (2004) 94-99
93. Coopersmith C.M., Brennan D.C., Miller B., et al. Renal transplantation following previous heart, liver, and lung transplantation: an 8-year single-center experience. Surgery 130 (2001) 457-462
94. Shihab F.S. Renin-angiotensin system in chronic renal allograft dysfunction. Contrib Nephrol 135 (2001) 222-234
95. Shihab F.S. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin Nephrol 16 (1996) 534-547